Oslo, Norway, 03 February 2026 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell
therapies for the treatment of solid cancers, today announced the promotion of
Emilie Gauthy to Chief Technology Officer (CTO). Gauthy, who has played a
central role in building Zelluna's manufacturing and CMC capabilities since
joining in 2022, assumes the role with immediate effect.
In her role as CTO, Gauthy will continue to lead Zelluna's manufacturing and CMC
strategy as the company advances its clinical development program, scales up
manufacturing capacity and expands the pipeline of its off-the-shelf TCR-NK
platform.
Under Gauthy's leadership, Zelluna has established a scalable manufacturing
process and analytical capabilities that enabled the company to successfully
submit its Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in
December 2025. Key achievements include locking the manufacturing process,
producing and quality-testing a GMP clinical batch, and establishing the CMC
foundation for the company's first-in-human clinical trial, with initial data
expected to emerge from mid-2026. These achievements also enable the entire TCR-
NK platform supporting the continuous development of future programs.
"Emilie has been central to building the manufacturing and CMC capabilities that
enabled us to submit our first CTA," said Namir Hassan, CEO of Zelluna. "Her
promotion to CTO recognizes her leadership in establishing the foundation that
has taken ZI-MA4-1 into clinical development and can be applied across the
pipeline enabling our entire TCR-NK platform."
"I am proud of what we have achieved as a team since 2022," said Emilie Gauthy,
CTO of Zelluna. "Submitting our first CTA was a major milestone, and we have
built strong manufacturing foundations to enable our scalable off-the-shelf TCR-
NK platform. I look forward to supporting the clinical development of ZI-MA4-1
and prepare for the future."
About Zelluna ASA
Zelluna ASA (OSE: ZLNA) is pioneering allogeneic "off-the-shelf" T Cell
Receptor-based Natural Killer (TCR-NK) cell therapies for solid cancers. The
company's lead candidate, ZI-MA4-1, is the world's first MAGE-A4 targeting TCR-
NK therapy. Zelluna submitted its Clinical Trial Application to the UK MHRA in
December 2025, with initial clinical data expected to emerge from mid-2026.
Zelluna is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange under the ticker ZLNA.
For more information, please visit www.zelluna.com (http://www.zelluna.com/)
For further information, please contact:
Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)
Phone: +44 7720 687608